NASDAQ:IDXG - Interpace Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.00
  • Forecasted Upside: 1.12 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$8.90
+0.30 (1.20%)
Get New Interpace Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IDXG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IDXG

Analyst Price Target is $9.00
▲ +1.12% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Interpace Biosciences in the last 3 months. The average price target is $9.00, with a high forecast of $11.00 and a low forecast of $7.00. The average price target represents a 1.12% upside from the last price of $8.90.

This chart shows the closing price for IDXG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Interpace Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/21/2021HC WainwrightBoost Price TargetPositive ➝ Buy$9.00 ➝ $11.00Low
4/15/2021HC WainwrightBoost Price TargetBuy$6.00 ➝ $9.00N/A
4/9/2021HC WainwrightReiterated RatingBuy$6.00 ➝ $9.00Medium
1/25/2021HC WainwrightLower Price TargetBuy$10.00 ➝ $6.00High
10/22/2020Alliance Global PartnersLower Price TargetBuy$9.25 ➝ $7.00Low
10/22/2020HC WainwrightLower Price TargetBuy$11.00 ➝ $10.00Low
6/26/2020HC WainwrightReiterated RatingBuy$12.00 ➝ $11.00High
4/24/2020Maxim GroupReiterated RatingBuy$12.00High
4/23/2020Alliance Global PartnersLower Price TargetBuy$21.00 ➝ $9.25High
4/23/2020HC WainwrightLower Price TargetBuy$15.00 ➝ $12.00High
4/15/2020Janney Montgomery ScottInitiated CoverageBuyHigh
3/3/2020HC WainwrightReiterated RatingBuy$15.00Low
2/12/2020HC WainwrightReiterated RatingBuy$15.00Medium
1/21/2020HC WainwrightReiterated RatingBuyLow
1/7/2020HC WainwrightReiterated RatingBuy$2.00High
12/18/2019HC WainwrightReiterated RatingBuy$2.00Low
11/14/2019HC WainwrightReiterated RatingBuy$2.00High
11/5/2019HC WainwrightReiterated RatingBuyMedium
10/25/2019HC WainwrightReiterated RatingBuyHigh
10/21/2019Maxim GroupSet Price TargetBuy$2.00High
10/18/2019HC WainwrightSet Price TargetBuy$2.00High
10/1/2019HC WainwrightReiterated RatingBuy$2.00Medium
9/26/2019OppenheimerInitiated CoverageOutperform$3.00 ➝ $3.00High
7/19/2019HC WainwrightSet Price TargetBuy$2.00Medium
6/21/2019HC WainwrightReiterated RatingBuyLow
5/14/2019HC WainwrightSet Price TargetBuy$4.00Medium
3/20/2019Maxim GroupReiterated RatingBuy$4.00High
2/20/2019HC WainwrightReiterated RatingBuy$3.00High
11/27/2018HC WainwrightSet Price TargetBuy$3.00Medium
11/26/2018Maxim GroupSet Price TargetBuy$4.00Medium
11/14/2018HC WainwrightSet Price TargetBuy$3.00High
11/14/2018Maxim GroupSet Price TargetBuy$4.00High
11/8/2018HC WainwrightReiterated RatingBuy$3.00N/A
11/7/2018Maxim GroupSet Price TargetBuy$4.00Low
10/17/2018Dawson JamesInitiated CoverageBuy$4.00High
10/15/2018Maxim GroupSet Price TargetBuy$4.00Low
10/11/2018HC WainwrightSet Price TargetBuy$3.00Medium
10/5/2018HC WainwrightSet Price TargetBuy$3.00High
9/25/2018HC WainwrightReiterated RatingBuy$3.00Low
9/24/2018Maxim GroupReiterated RatingBuy$4.00Low
8/10/2018HC WainwrightSet Price TargetBuy$3.00Low
8/10/2018Maxim GroupReiterated RatingBuy$3.00Low
7/27/2018HC WainwrightSet Price TargetBuy$3.00Low
7/20/2018HC WainwrightReiterated RatingBuy$3.00Low
7/19/2018Maxim GroupSet Price TargetBuy$3.00Medium
6/22/2018LADENBURG THALM/SH SHInitiated CoverageBuy$2.25Low
6/12/2018HC WainwrightSet Price TargetBuy$3.00Low
6/11/2018Maxim GroupSet Price TargetBuy$3.00Low
5/30/2018Maxim GroupReiterated RatingBuy$3.00Low
5/17/2018HC WainwrightSet Price TargetBuy$3.00Low
5/11/2018HC WainwrightSet Price TargetBuy$3.00Medium
4/6/2018HC WainwrightSet Price TargetBuy$3.00Medium
3/28/2018Maxim GroupSet Price TargetBuy$3.00High
3/16/2018Maxim GroupSet Price TargetBuy$3.00Low
3/16/2018HC WainwrightSet Price TargetBuy$3.00High
3/8/2018HC WainwrightInitiated CoverageBuy$3.00High
2/22/2018LaidlawInitiated CoverageBuy ➝ Buy$4.50High
2/14/2018Maxim GroupReiterated RatingBuy ➝ Buy$5.00 ➝ $3.00Medium
11/14/2017Maxim GroupReiterated RatingBuy$5.00N/A
8/15/2017Maxim GroupInitiated CoverageBuy ➝ Buy$5.00High
(Data available from 9/19/2016 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
2/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/22/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/21/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/19/2021

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Interpace Biosciences logo
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Read More

Today's Range

Now: $8.90
Low: $8.85
High: $9.00

50 Day Range

MA: $8.06
Low: $4.75
High: $10.40

52 Week Range

Now: $8.90
Low: $2.57
High: $10.42

Volume

2,109 shs

Average Volume

5,780 shs

Market Capitalization

$37.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24

Frequently Asked Questions

What sell-side analysts currently cover shares of Interpace Biosciences?

The following Wall Street research analysts have issued stock ratings on Interpace Biosciences in the last year: Alliance Global Partners, HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for IDXG.

What is the current price target for Interpace Biosciences?

2 Wall Street analysts have set twelve-month price targets for Interpace Biosciences in the last year. Their average twelve-month price target is $9.00, suggesting a possible upside of 1.1%. HC Wainwright has the highest price target set, predicting IDXG will reach $11.00 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $7.00 for Interpace Biosciences in the next year.
View the latest price targets for IDXG.

What is the current consensus analyst rating for Interpace Biosciences?

Interpace Biosciences currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IDXG will outperform the market and that investors should add to their positions of Interpace Biosciences.
View the latest ratings for IDXG.

What other companies compete with Interpace Biosciences?

How do I contact Interpace Biosciences' investor relations team?

Interpace Biosciences' physical mailing address is MORRIS CORPORATE CENTER 1 BUILDING C 300 INTERPACE PARKWAY, PARSIPPANY NJ, 07054. The business services provider's listed phone number is 855-776-6419 and its investor relations email address is [email protected] The official website for Interpace Biosciences is www.interpace.com.